



PTO/SB/05 (4/98)

Please type a plus sign (+) inside this box 

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless, it displays a valid OMB control number.

## UTILITY PATENT APPLICATION **TRANSMITTAL**

Attorney Docket No. IMUNE-001A First Inventor or Application Identifier R . J Zahradnik PEPTIDE ANTIGENS ANTIBODIES AND

See MPEP	APPLICATION ELEMENTS chapter 600 concerning utility patent application contents.	Assistant Commissioner for Patents  ADDRESS TO: Box Patent Application  Washington, DC, 20231
	* Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)	5. Microfiche Computer Program (Appendix)
2. X	Specification [Total Pages 21]	6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
	- Descriptive title of the Invention	a. Computer Readable Copy
	- Cross References to Related Applications	b. Paper Copy (identical to computer copy)
	- Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix	c. Statement verifying identity of above copies
	- Backgroung of the Invention	ACCOMPANYING APPLICATION PARTS
	- Brief Summary of the Invention	
-	- Brief Description of the Drawings (if filed)	7. X Assignment Papers (cover sheet & document(s))
-	- Detailed Description	8. X 37 C.F.R.§3.73(b) Statement Power of (when there is an assignee) X Attorney
- I	- Claim(s)	9. English Translation Document (if applicable)
	- Abstract of the Disclosure	Information Disclosure Copies of IDS
3. X	Drawing(s) (35 U.S.C. 113) [Total Sheets 4]	Statement (IDS)/PTO-1449 Citations
4. Oath o	or Declaration [Total Pages 25]	11. Preliminary Amendment
a.	X Newly executed (original or copy)	12. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
b.	Copy from a prior application (37 C.F.R. § 1.63(d) (for centinuation/divisional with Box 16 completed)	Statement filed in prior application
	DELETION OF INVENTOR(S)	13. Statement(s) Status still proper and desired
	Signed statement attached deleting inventor(s) named in the prior application,	14. Certified Copy of Priority Document(s) (if foreign priority is claimed)
	see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).	15. Other:
	OR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY	13. Other.
IF ONE FIL	MALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT LED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).	
16. <u>If a</u> C	CONTINUING APPLICATION, check appropriate box, and sup	oply the requisite information below and in a preliminary amendment
	Continuation Divisional Continuation-in-part (CIF	
	application information: Examiner   NUATION or DIVISIONAL APPS only: The entire disclosure of	Group : Art Unit:  f the prior application, from which an oath or declaration is supplied
under Box	4b, is considered a part of the disclosure of the accompanying	ng continuation or divisional application and is hereby incorporated by as been inadvertently omitted from the submitted application parts.
reference.	17. CORRESPONDEN	
	00	
Cust	tomer Number or Bar Code Label 007663 (Insert Customer No. or Attack	:
Name	STETINA BRUNDA BARRED & B	BRUCKER
	0.4004	
Address	24221 Calle de la Louisa,	4th Floor
City	Laguna Hills State	CA
Country	USA Telephone	(949)855_1246
Name		
-	Matthew A. Newbores	30,224
Signat	we HIME WHALLE	$-$ Dec $\frac{Date}{C}$ Dec $\frac{D}{C}$ 2000

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Officer. Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

ATTORNEY DOCKET NO: IMUNE-001A TITLE: ANTIBODIES AND PEPTIDE ANTIGENS FOR PRODUCING ANTIBODIES HAVING A SELECTIVE BINDING SPECIFICITY TO BIOACTIVE INTACT PARATHYROID HORMONE (PTH) 1-84

## Certificate of Mailing under 37 CFR 1.8 or 37 CFR 1.10

	I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:	
V	I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, Express Mail No. <u>EL661568746US</u> addressed to:	
	Box New Applications Assistant Commissioner for Patents Washington, D.C. 20231	
	on <u>12-5-00</u> (Date)	
	Yhell Delivede	
	#ignature	
	MICHELLE SCHROEDER	
	Typed or printed name of person signing Certificate	
Note:	Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.	
1. 2. 3. 4. 5. 6. 7. 8. 9.	Utility Patent Application; Fee Transmittal, in duplicate; Check for \$551.00 (patent \$511.00 and assignment \$40.00) Utility Patent Application (21 pages) plus drawings (4 pages); Declaration for Utility or Design Patent Application (3 pages); Power of Attorney; Certificate under 37 CFR Section 3.73 (b); Recordation Form Cover Sheet - Patents Only; Assignments (two assignments, one property) Return postcard.	

PTO/SB/17 (09-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL	AMOUNT	OF	<b>PAYMENT</b>
-------	--------	----	----------------

(\$) 551.00

Complete if Known				
Application Number	unknown			
Filing Date	herewith			
First Named Inventor	R.J. Zahradnik			
Examiner Name				
Group Art Unit				
Attorney Docket No.	TMUNE 0013			

METHOD OF PAYMENT	FEE CALCULATION (continued)		
1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to	3. ADDITIONAL FEES		
Deposit	Large Entity Small Entity Fee Fee Fee Fee See December 1		
Account 19-4330	Code (\$) Code (\$)	Fee Paid	
Deposit	105 130 205 65 Surcharge - late filing fee or oath		
Account Stetina Brunda	127 50 227 25 Surcharge - late provisional filing fee or cover sheet		
Charge Any Additional Fee Required Under 37 CFR 1.18 and 1.17	139 130 139 130 Non-English specification		
Applicant claims small entity status. See 37 CFR 1 27	147 2,520 147 2,520 For filing a request for ex parte reexamination		
2. X Payment Enclosed:	112 920* 112 920* Requesting publication of SIR prior to Examiner action		
Check Credit card Order Other	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action		
FEE CALCULATION	115 110 215 55 Extension for reply within first month		
1. BASIC FILING FEE	116 390 216 195 Extension for reply within second month		
Large Entity Small Entity	117 890 217 445 Extension for reply within third month		
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	118 1,390 218 695 Extension for reply within fourth month		
101 710 201 355 Utility filing fee	128 1,890 228 945 Extension for reply within fifth month		
106 320 206 160 Design filing fee	119 310 219 155 Notice of Appeal		
107 490 207 245 Plant filing fee	120 310 220 155 Filing a brief in support of an appeal		
108 710 208 355 Reissue filing fee	121 270 221 135 Request for oral hearing		
114 150 214 75 Provisional filing fee	138 1,510 138 1,510 Petition to institute a public use proceeding		
SUBTOTAL (1) (\$) 355	140 110 240 55 Petition to revive - unavoidable		
	141 1,240 241 620 Petition to revive - unintentional		
2. EXTRA CLAIM FEES Fee from	142 1,240 242 620 Utility issue fee (or reissue)		
Extra Claims below Fee Paid			
Total Claims $24 - 20^{\circ} = 4 \times 9 = 36$ Independent $6 - 3^{\circ} = 3 \times 40 = 120$			
Claims — — — — — — — — — — — — — — — — — — —	The state of the continuation of the continuation of		
	as a second to provisional applications		
Large Entity Small Entity			
Fee Fee Fee Fee Description Code (\$) Code (\$)	581 40 581 40 Recording each patent assignment per property (times number of properties)	40	
103 18 203 9 Claims in excess of 20	146 710 246 355 Filing a submission after final rejection (37 CFR § 1.129(a))	];	
102 80 202 40 Independent claims in excess of 3	149 710 249 355 For each additional invention to be		
104 270 204 135 Multiple dependent claim, if not paid	examined (37 CFR § 1.129(b))		
109 80 209 40 ** Reissue independent claims over original patent	179 710 279 355 Request for Continued Examination (RCE)		
110 18 210 9 "Reissue claims in excess of 20 and over original patent	169 900 169 900 Request for expedited examination of a design application		
SUBTOTAL (2) (\$) 156			
**Or number previously paid, if greater; For Reissues, see above Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 4.0			

SUBMITTED BY Complete (if applicable) Registration No Matthew A. Name (PnntiType) Newboles Telephone 36,224 949)855-1 (Attorney/Agent) Signature Date 2000 Dec.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

## CERTIFICATE UNDER 37 CF.R. § 3.73(b)

	nt: R.J. ZAHRADNIK, et al. tion No.:	Filed:
For: _AN	NTIBODIES AND PEPTIDE ANTIGE	NS FOR PRODUCING ANTIBODIES HAVING BIOACTIVE INTACT PARATHYROID HORMONE
IMMUNO! (Name of As	OTOPICS, INC., a_Assignee)	California Corp. (PTH) 1-84 (Type of Assignee, e.g., corporation, partnership, etc.)
certifies that	at it is the assignee of the entire right, title and interest	in the patent application identified by virtue of either:
A. [X] Ar Pa	An assignment from the inventor(s) of the patent applicatent and Trademark Office at Reel, Fr	cation identified above. The assignment was recorded in the ame, or for which a copy thereof is attached.
OR		
B. [ ] A	chain of title from the inventor(s), of the patent appli	cation identified above, to the current assignee as shown below:
1.	. From: To	DI
	The document was recorded in the Patent and Reel, or	Trademark Office at
2.	. From: To To The document was recorded in the Patent and	r
	The document was recorded in the Patent and Reel, Frame, or	Trademark Office at for which a copy thereof is attached.
3.		
	The document was recorded in the Patent and Reel, Frame, or	Trademark Office at
[ ]	] Additional documents in the chain of title are	listed on a supplemental sheet.
	Copies of assignments or other documents in	the chain of title are attached.
The undersigned's	gned has reviewed all the documents in the chain of ti	tle of the patent application identified above and, to the best of fied above.
The undersign	gned (whose title is supplied below) is empowered to	act on behalf of the assignee.
belief are beli like so made,	lieved to be true; and further, that these statements are	edge are true, and that all statements made on information and made with the knowledge that willful false statements, and the der Section 1001, Title 18 of the United States Code, and that olication or any patent issuing thereon.
Date.	12-5-00	
Name: Ri	ichard J. Zahradnik	
Registration N	No.: (if app	olicable)
Title <u>Pre</u>	esident of Immunotopics, Inc	•
Signature:	Richard Q. 7 almachib	